Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers and develops medicines to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating cortisol activity. It markets Korlym (mifepristone) and an authorized generic in the United… From the company’s description.
In fiscal 2025, Corcept Therapeutics Incorporated reported revenue of $761.41M, up 12.8% from fiscal 2024, and net income of $99.65M. Its operating margin was 5.9%, and operations generated $142.00M in cash. Over the twelve months to Jun 30, 2026, revenue was $830.81M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Corcept Therapeutics Incorporated does
In the company’s own words
Corcept Therapeutics Incorporated (Nasdaq: CORT) is a commercial-stage biopharmaceutical company that discovers and develops medicines to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating cortisol activity. It markets Korlym (mifepristone) and an authorized generic in the United States for hypercortisolism, selling through physician-focused representatives and specialty pharmacy services. Its pipeline includes selective cortisol modulators: relacorilant for hypercortisolism and cancers, nenocorilant for use with immunotherapy, miricorilant for MASH, and dazucorilant for ALS. The company’s clinical programs also include combinations with chemotherapy and other cancer treatments. Corcept’s business is organized around its commercialized hypercortisolism products and research and development programs; it reports no operating segments in the supplied business description. It relies on contract manufacturers to produce its products and product candidates. In fiscal 2025, revenue was $[amount not provided in the supplied text], and research and development expense was $254.9 million. Its website is https://www.corcept.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- REDWOOD CITY, CA
- Fiscal year end
- December
- CIK
- 1088856
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Corcept Therapeutics Incorporated — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Corcept Therapeutics Incorporated’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Corcept Therapeutics Incorporated and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Corcept Therapeutics Incorporated's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Corcept Therapeutics Incorporated's last four quarterly filings that the numbers alone won't show?”